MiR-320a inhibits gastric carcinoma by targeting activity in the FoxM1-P27KIP1 axis

MicroRNAs (miRNAs) regulate tumorigenesis by inhibiting gene expression. In this study, we showed that miR-320a expression is decreased in human gastric cancer tissues and correlates inversely with expression of FoxM1, a key cell cycle regulator involved in gastric carcinoma. By contrast, the expression of P27KIP1, a downstream effector of FoxM1, correlates positively with miR-320a levels. Luciferase assays indicate that miR-320a suppresses FoxM1 expression, and in vitro recovery tests using FoxM1 siRNA indicate miR-320a inhibits gastric cancer cell proliferation by suppressing activity in the FoxM1-P27KIP1 axis. In vivo, nude mice injected with BGC-823 gastric cancer cells expressing a miR-320a inhibitor exhibit faster tumor growth than mice injected with control cells. Analysis of FoxM1 and P27KIP1 expression in tumor tissues indicates that miR-320a suppression increases the tumor growth by enhancing FoxM1-P27KIP1 signaling. These results thus reveal the crucial role played by miR-320a in limiting gastric carcinoma by directly targeting FoxM1- P27KIP1 axis.

[1]  Yong Huang,et al.  Biological functions of microRNAs: a review , 2011, Journal of Physiology and Biochemistry.

[2]  A. Gartel,et al.  FOX(M1) News—It Is Cancer , 2013, Molecular Cancer Therapeutics.

[3]  A. Jemal,et al.  Global Patterns of Cancer Incidence and Mortality Rates and Trends , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[4]  C. Croce,et al.  microRNA involvement in human cancer. , 2012, Carcinogenesis.

[5]  C. Croce,et al.  MicroRNAs and chromosomal abnormalities in cancer cells , 2006, Oncogene.

[6]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[7]  Joon-Oh Park,et al.  Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  C. Croce,et al.  MicroRNAs in Cancer. , 2009, Annual review of medicine.

[9]  X. Ying,et al.  MicroRNA-194 Inhibits the Epithelial–Mesenchymal Transition in Gastric Cancer Cells by Targeting FoxM1 , 2014, Digestive Diseases and Sciences.

[10]  F. Kiessling,et al.  MicroRNA-126-5p promotes endothelial proliferation and limits atherosclerosis by suppressing Dlk1 , 2014, Nature Medicine.

[11]  Huan Yang,et al.  MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. , 2008, Cancer research.

[12]  Lei Yang,et al.  MiR-320a contributes to atherogenesis by augmenting multiple risk factors and down-regulating SRF , 2015, Journal of cellular and molecular medicine.

[13]  T. Zhu,et al.  MicroRNA-320a sensitizes tamoxifen-resistant breast cancer cells to tamoxifen by targeting ARPP-19 and ERRγ* , 2015, Scientific Reports.

[14]  Suyun Huang,et al.  Down-regulation of microRNA-494 via loss of SMAD4 increases FOXM1 and β-catenin signaling in pancreatic ductal adenocarcinoma cells. , 2014, Gastroenterology.

[15]  Hyun Jung Park,et al.  FoxM1: a master regulator of tumor metastasis. , 2011, Cancer research.

[16]  A. Farooqi.  miRNA Regulation of DNA Damage Repair Proteins in Cancer Cells: Interplay of ATM, TRAIL and miRNA , 2014 .

[17]  S. Lawler,et al.  MicroRNAs in cancer: biomarkers, functions and therapy. , 2014, Trends in molecular medicine.

[18]  M. Tewari,et al.  MicroRNA profiling: approaches and considerations , 2012, Nature Reviews Genetics.

[19]  A. Gartel,et al.  Targeting FOXM1 in cancer. , 2013, Biochemical pharmacology.

[20]  Dong Wang,et al.  Human MicroRNA Oncogenes and Tumor Suppressors Show Significantly Different Biological Patterns: From Functions to Targets , 2010, PloS one.

[21]  R. DeMatteo,et al.  Updates on the management of gastrointestinal stromal tumors. , 2012, Surgical oncology clinics of North America.

[22]  Yiwei Li,et al.  MicroRNA and Cancer: Tiny Molecules with Major Implications , 2008, Current genomics.

[23]  Jiping Zeng,et al.  The tumor suppressive role of miRNA-370 by targeting FoxM1 in acute myeloid leukemia , 2012, Molecular Cancer.

[24]  L. Ouyang,et al.  Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis , 2012, Cell proliferation.

[25]  M. Esteller.  Non-coding RNAs in human disease , 2011, Nature Reviews Genetics.

[26]  C. Harris,et al.  Genetic variation in microRNA networks: the implications for cancer research , 2010, Nature Reviews Cancer.

[27]  M. Björkholm,et al.  FoxM1 is up‐regulated in gastric cancer and its inhibition leads to cellular senescence, partially dependent on p27kip1 , 2009, The Journal of pathology.

[28]  J. Xiong,et al.  miR-149 Inhibits Non-Small-Cell Lung Cancer Cells EMT by Targeting FOXM1 , 2013, Biochemistry research international.

[29]  N. Seki,et al.  Tumour‐suppressive microRNA‐24‐1 inhibits cancer cell proliferation through targeting FOXM1 in bladder cancer , 2014, FEBS letters.

[30]  Peng Jin,et al.  Single nucleotide polymorphism associated with mature miR-125a alters the processing of pri-miRNA. , 2007, Human molecular genetics.

[31]  J. Voltas,et al.  [Treatment of gastric cancer]. , 1982, Revista de medicina de la Universidad de Navarra.

[32]  Jiping Zeng,et al.  Histone demethylase RBP2 decreases miR-21 in blast crisis of chronic myeloid leukemia , 2014, Oncotarget.

[33]  Q. Sun,et al.  Loss of microRNA-143/145 disturbs cellular growth and apoptosis of human epithelial cancers by impairing the MDM2-p53 feedback loop , 2013, Oncogene.

[34]  Ji-Lin Wang,et al.  Candidate microRNA Biomarkers in Human Gastric Cancer: A Systematic Review and Validation Study , 2013, PloS one.

[35]  Jun Yu,et al.  A Brief Review on the Mechanisms of miRNA Regulation , 2009, Genom. Proteom. Bioinform..

[36]  M. Blaser,et al.  Helicobacter pylori and gastrointestinal tract adenocarcinomas , 2002, Nature Reviews Cancer.

[37]  Farin Kamangar,et al.  Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  Yanhong Yu,et al.  miR‐134 inhibits epithelial to mesenchymal transition by targeting FOXM1 in non‐small cell lung cancer cells , 2012, FEBS letters.

[39]  Jing Zhao,et al.  MicroRNA-320a suppresses human colon cancer cell proliferation by directly targeting β-catenin. , 2012, Biochemical and biophysical research communications.

[40]  Yunhui Liu,et al.  MiR-320a down-regulation mediates bladder carcinoma invasion by targeting ITGB3 , 2014, Molecular Biology Reports.

[41]  K. Kelnar,et al.  Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. , 2010, Cancer research.

[42]  F. Slack,et al.  Oncomirs — microRNAs with a role in cancer , 2006, Nature Reviews Cancer.

[43]  C. Croce,et al.  MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review , 2012, EMBO molecular medicine.

[44]  J. Rutka,et al.  The Cell Cycle: Accelerators, Brakes, and Checkpoints , 2004, Neurosurgery.